Scientists have developed a groundbreaking gene therapy that targets pain-processing circuits in the brain without triggering addiction. Using AI to map how pain signals work, researchers created a precise "off switch" that delivers morphine-like relief while avoiding dangerous side effects. The therapy works like a volume control that turns down only pain signals, leaving normal brain function unaffected. In preclinical tests, it provided lasting pain relief without interfering with normal sensations or activating reward pathways linked to addiction. This represents the first brain-targeted gene therapy for pain management, potentially offering safer alternatives for over 50 million Americans living with chronic pain.
